Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
NCT ID: NCT04875299
Last Updated: 2021-08-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
480 participants
OBSERVATIONAL
2021-09-30
2023-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis
NCT01114880
Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases
NCT03339089
A Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing Spondylitis
NCT01901627
Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis
NCT00195819
A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
NCT05467995
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
adalimumab TDM
Patients with active ankylosing spondylitis receiving adalimumab treatment.
The study is observational
The study is observational
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The study is observational
The study is observational
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient who meets the definition of Ankylosing Spondylitis based on the 1984 Modified New York Criteria, has a diagnosis of active Ankylosing Spondylitis (BASDAI ≥ 4, Back pain ≥ 4).
3. Patients who have indication of adalimumab.
4. Patients on NSAIDs treatment need to be on a stable dose for at least 4 weeks.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine
OTHER
Central South University
OTHER
First Affiliated Hospital of Chongqing Medical University
OTHER
Tianjin First Central Hospital
OTHER
Wuxi No. 2 People's Hospital
OTHER
The First People's Hospital of Changzhou
OTHER
Affiliated Hospital of Nantong University
OTHER
Shandong Provincial Hospital
OTHER_GOV
Qingdao Municipal Hospital
OTHER
Liaocheng People's Hospital
OTHER
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
OTHER
The First Affiliated Hospital of Soochow University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Miao Liyan
vice president
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Liyan Miao, Ph.D
Role: STUDY_CHAIR
The Affiliated Hospital of Soochow University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ADL-TDM-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.